Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Pegylated L-Asparaginase

Status
Active
Cancer Type
Hodgkin Lymphoma
Lymphoma
Non-Hodgkin Lymphoma
Trial Phase
Phase III
Eligibility
1 to 17, Male and Female
Study Type
Supportive care
NCD ID
NCT02369653
Protocol IDs
CV185-155 (primary)
NCI-2015-01370
2014-000328-47
Study Sponsor
Bristol-Myers Squibb

Summary

The purpose of this study is to compare the effect of a blood thinning drug called Apixaban

versus no administration of a blood thinning drug, in preventing blood clots in children

with leukemia or lymphoma. Patients must be receiving chemotherapy; including Pegylated

L-Asparaginase and have a central line (a catheter inserted for administration of

medications and blood sampling).

Treatment Sites in Georgia

Aflac Cancer and Blood Disorders Center of Children’s at Egleston


1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322
404-785-0853
www.choa.org

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.